SCHEMBL6449310

SCHEMBL6449310

Oc1ccc(C23CC4CC(CC(C4)C2)C3)cc1Br

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.71
KMT2A Q03164 4/20 0.71
GAA P10253 2/20 0.71
POLB P06746 1/20 0.71
GFER P55789 1/20 0.71
LMNA P02545 3/20 0.47
ALDH1A1 P00352 3/20 0.47
EPHX2 P34913 3/20 0.44
NPC1 O15118 1/20 0.41
ALOX15 P16050 2/20 0.41
MAPT P10636 2/20 0.40
RAB9A P51151 1/20 0.39
HIF1A Q16665 3/20 0.38
EPAS1 Q99814 2/20 0.38
RARA P10276 2/20 0.38
RARB P10826 2/20 0.38
RARG P13631 2/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20790078 0.93 MEN1 (0.59) MEN1KMT2AGAAPOLBGFER
SCHEMBL3975182 0.90 MEN1 (0.57) MEN1KMT2AGAAPOLBGFER
SCHEMBL559964 0.83 MEN1 (1.00) MEN1KMT2AGAAPOLBGFER
SCHEMBL2710580 0.81 MEN1 (0.76) MEN1KMT2AGAAPOLBGFER
SCHEMBL549446 0.80 MEN1 (0.73) MEN1KMT2AGAAPOLBGFER
SCHEMBL14829735 0.79 MEN1 (0.71) MEN1KMT2AGAAPOLBGFER
SCHEMBL2710154 0.79 MEN1 (0.71) MEN1KMT2AGAAPOLBGFER
SCHEMBL22453632 0.79 ALDH1A1 (0.56) MEN1KMT2AGAAPOLBGFER
SCHEMBL3175871 0.79 MEN1 (0.51) MEN1KMT2AGAAPOLBGFER
SCHEMBL14829050 0.79 MEN1 (0.71) MEN1KMT2AGAAPOLBGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195424-B2 Antibiotic compounds THE GENERAL HOSPITAL CORPORATION (US) 2025-01-14 US disclosed
US-20220095614-A1 Antibiotic Compounds THE GENERAL HOSPITAL CORPORATION 2022-03-31 US disclosed
US-20220095614-A1 Antibiotic Compounds THE GENERAL HOSPITAL CORPORATION 2022-03-31 US disclosed
US-11278025-B2 Antibiotic compounds THE GENERAL HOSPITAL CORPORATION (US) 2022-03-22 US disclosed
CN-110885320-B Process for producing tertiary amine compound 陕西莱特光电材料股份有限公司 2020-11-10 CN disclosed
US-20200190009-A1 Antibiotic Compounds TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-06-18 US disclosed
US-20200190009-A1 Antibiotic Compounds TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2020-06-18 US disclosed
CN-110240546-B Preparation method of adamantyl-containing triphenylamine derivative 陕西莱特光电材料股份有限公司 2020-04-17 CN disclosed
CN-110885320-A Process for producing tertiary amine compound 陕西莱特光电材料股份有限公司 2020-03-17 CN disclosed
WO-2018213609-A1 ANTIBIOTIC COMPOUNDS AUSUBEL FREDERICK M (US) 2018-11-22 WO disclosed
US-20050014767-A1 Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases INCYTE CORPORATION 2005-01-20 US disclosed
WO-2004066952-A2 BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES INCYTE CORPORATION (US) 2004-08-12 WO disclosed
US-20040097566-A1 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer INCYTE SAN DIEGO INCORPORATED 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014767-A1 Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases AR, CCNT1, BRD1 MEN1 3126/4885KMT2A 1609/4885GAA 3018/4885
US-20200190009-A1 Antibiotic Compounds CUTA, NRDC, CLPP MEN1 4344/4885KMT2A 4368/4885GAA 1644/4885
US-20220095614-A1 Antibiotic Compounds CUTA, NRDC, CLPP MEN1 4344/4885KMT2A 4368/4885GAA 1644/4885
US-12195424-B2 Antibiotic compounds CUTA, NRDC, CLPP MEN1 4344/4885KMT2A 4368/4885GAA 1644/4885
US-20040097566-A1 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer PTPA, PTPRC, PTPRCAP MEN1 3865/4885KMT2A 1090/4885GAA 1045/4885
US-11278025-B2 Antibiotic compounds CUTA, NRDC, CLPP MEN1 4344/4885KMT2A 4368/4885GAA 1644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.